Edition:
India

Merck & Co Inc (MRK.N)

MRK.N on New York Stock Exchange

79.81USD
15 Feb 2019
Change (% chg)

$0.87 (+1.10%)
Prev Close
$78.94
Open
$79.71
Day's High
$80.13
Day's Low
$79.29
Volume
3,671,822
Avg. Vol
4,343,280
52-wk High
$80.18
52-wk Low
$52.83

Latest Key Developments (Source: Significant Developments)

Merck & Co Inc CEO Says Not Focusing On Mega-Mergers - Conf. Call
Friday, 1 Feb 2019 

Feb 1 (Reuters) - Merck & Co Inc ::MERCK & CO INC CEO SAYS NOT FOCUSING ON LARGE MEGA-MERGERS - CONF. CALL.MERCK & CO INC SAYS SHARES THE U.S. ADMINISTRATION’S GOAL OF LOWERING OUT-OF-POCKET COSTS FOR PATIENTS -CONF. CALL.  Full Article

Merck & Co -Sees Capital Investments Of $16 Billion Over 5 Years, Including Expanding Manufacturing Capacity For Oncology, Vaccines & Animal Health
Friday, 1 Feb 2019 

Feb 1 (Reuters) - Merck & Co Inc ::MERCK & CO -SEES CAPITAL INVESTMENTS OF $16 BILLION OVER 5 YEARS, INCLUDING EXPANDING MANUFACTURING CAPACITY FOR ONCOLOGY, VACCINES & ANIMAL HEALTH.  Full Article

Merck Sets Quarterly Dividend Of $0.55 Per Share
Wednesday, 30 Jan 2019 

Jan 29 (Reuters) - Merck & Co Inc ::SETS QUARTERLY DIVIDEND OF $0.55 PER SHARE.  Full Article

U.S. FDA Releases Label On Its Website For Samsung Bioepsis' Ontruzant
Saturday, 19 Jan 2019 

Jan 18 (Reuters) - U.S. Food and Drug Administration::U.S. FDA RELEASES LABEL ON ITS WEBSITE FOR SAMSUNG BIOEPSIS CO LTD'S ONTRUZANT.U.S. FDA - ONTRUZANT IS A HER2/NEU RECEPTOR ANTAGONIST INDICATED FOR THE TREATMENT OF HER2-OVEREXPRESSING BREAST CANCER.U.S. FDA - ONTRUZANT IS ALSO INDICATED FOR TREATMENT OF HER2-OVEREXPRESSING METASTATIC GASTRIC/GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA.U.S. FDA - ONTRUZANT (TRASTUZUMAB-DTTB) IS BIOSIMILAR TO HERCEPTIN (TRASTUZUMAB).U.S. FDA - WARNS THAT ONTRUZANT, TRASTUZUMAB PRODUCTS CAN RESULT IN CARDIOMYOPATHY, INFUSION REACTIONS, EMBRYO-FETAL TOXICITY, & PULMONARY TOXICITY.  Full Article

Samsung Bioepsis Wins FDA Approval For Ontruzant - FDA Website
Saturday, 19 Jan 2019 

Jan 18 (Reuters) - U.S. Food and Drug Administration::SAMSUNG BIOEPSIS CO LTD WINS FDA APPROVAL FOR ONTRUZANT - FDA WEBSITE.  Full Article

Alopexx Vaccine Announces Licensing Agreement With Merck Animal Health
Tuesday, 15 Jan 2019 

Jan 14 (Reuters) - Alopexx Vaccines, LLC: :ALOPEXX VACCINE ANNOUNCES LICENSING AGREEMENT WITH MERCK ANIMAL HEALTH.ALOPEXX VACCINE - FINANCIAL TERMS OF AGREEMENT WITH MERCK WERE NOT DISCLOSED.ALOPEXX VACCINE - AGREEMENT WITH MERCK ANIMAL HEALTH TO DEVELOP AND COMMERCIALIZE ITS PNAG VACCINE FOR RHODOCOCCUS EQUI PNEUMONIA IN FOALS.  Full Article

Astrazeneca Says Lynparza Met Primary Endpoint In Solo-3 Trial
Thursday, 20 Dec 2018 

Dec 20 (Reuters) - AstraZeneca PLC ::ASTRAZENECA PLC - LYNPARZA MEETS PRIMARY ENDPOINT IN SOLO-3 TRIAL.ASTRAZENECA PLC - LYNPARZA MEETS PRIMARY ENDPOINT IN PHASE III SOLO-3 TRIAL FOR TREATMENT OF RELAPSED BRCA-MUTATED ADVANCED OVARIAN CANCER.ASTRAZENECA PLC - ASTRAZENECA AND MSD NOW PLAN TO DISCUSS RESULTS WITH FDA.  Full Article

FDA Approves Pembrolizumab For Merkel Cell Carcinoma
Thursday, 20 Dec 2018 

Dec 19 (Reuters) - U.S. FDA ::FDA APPROVES PEMBROLIZUMAB FOR MERKEL CELL CARCINOMA.U.S. FDA SAYS RECOMMENDED PEMBROLIZUMAB DOSE FOR MCC IS 200 MG ADMINISTERED AS 30-MINUTE INTRAVENOUS INFUSION EVERY 3 WEEKS FOR ADULTS.  Full Article

European Commission Approves Merck's Keytruda As Adjuvant Therapy For Adults With Resected Stage III Melanoma
Monday, 17 Dec 2018 

Dec 17 (Reuters) - Merck & Co Inc ::EUROPEAN COMMISSION APPROVES MERCK’S KEYTRUDA® (PEMBROLIZUMAB) AS ADJUVANT THERAPY FOR ADULTS WITH RESECTED STAGE III MELANOMA.MERCK & CO INC - APPROVAL ALLOWS MARKETING OF KEYTRUDA IN NEW INDICATION IN ALL 28 EU MEMBER STATES PLUS ICELAND, LICHTENSTEIN AND NORWAY.  Full Article

Roche Collaborates With Merck To Develop Companion Diagnostic Test To Identify Patients Eligible For Anti-Pd-1 Therapy
Tuesday, 11 Dec 2018 

Dec 11 (Reuters) - Roche Holding AG ::ROCHE TO DEVELOP COMPANION DIAGNOSTIC TEST TO HELP IDENTIFY PATIENTS ELIGIBLE FOR ANTI-PD-1 THERAPY BASED ON BIOMARKER EXPRESSION, NOT LOCATION, OF SOLID TUMORS.ROCHE HOLDING AG - WILL SEEK FDA APPROVAL FOR BIOMARKER PANEL EXPECTED TO PROVIDE A STANDARDIZED PREDICTIVE TESTING OPTION FOR DMMR.ROCHE HOLDING AG - ENTERED COLLABORATION WITH MERCK TO DEVELOP A COMPANION DIAGNOSTIC TEST TO IDENTIFY PATIENTS ELIGIBLE FOR ANTI-PD-1 THERAPY.ROCHE HOLDING AG - COMPANIES WILL COLLABORATE ON DEVELOPMENT OF A PAN-CANCER COMPANION DIAGNOSTIC.  Full Article

Photo

Merck to further study Keytruda in prostate cancer after early success

Merck & Co Inc said on Thursday it was launching three late-stage studies for its cancer immunotherapy Keytruda as a combination treatment for prostate cancer after the drug showed anti-tumor activity in an early-stage trial.